Introduction
Guy Goodwin is a senior research fellow and until recently was the W.A. Handley Professor of Psychiatry at the University of Oxford (2014). A fellow of the Academy of Medical Sciences, Goodwin has served as principal investigator in many clinical trials for the treatment of bipolar disorder. He has also been on the advisory boards of numerous research councils. He is currently the President of the European College of Neuropsychopharmacology.
Career
Research focus/interests
Goodwin's research focuses on the neurobiology ofmood disorders, notably bipolar disorder and its treatment. In addition to developing novel treatments formood disorders, Goodwin is interested in the impact of treatments on both the physiological and psychological levels, usingbrain imaging techniques to study the effects of treatment on brain structure and function as well as the connection between depression and memory impairment.
Notable contributions to research
Goodwin's findings on the impact of depression on brain tissue and memory have led to greater interest in neurogenesis when developingantidepressants as well as the role of cognition in the treatment of depression.
Goodwin was the principal investigator of many clinical trials for treatments of bipolar affective disorder, including the BALANCE, CEQUEL, and OXTEXT studies. He serves on the advisory boards of many biopharmaceutical companies including AstraZeneca and Pfizer.
Past appointments
After completing his DPhil in Neurophysiology atOxford, Goodwin qualified in psychiatry and went on to become a Clinical Scientist and Consultant Psychiatrist in the MRC Brain Metabolism Unit at the University of Edinburgh for 10 years. He then returned toOxford as Professor of Psychiatry.
Professor Goodwin has been the head ofOxford University's Department of Psychiatry since 2006, and a fellow of Merton College, Oxford since 1996.
Awards
Goodwin has won numerous awards, most recently the Mogens Schou Award for Research (2009) and the NHS Live Innovation Award with Professor John Geddes for developing the True Colours system that allowed them to remotely monitor the symptoms of theirbipolar patients.
Positions of trust and research assessments
Dr. Goodwin is currently President of the European College of Neuropsychopharmacology (2013–16). From 1997 to 2007, he was the non-executive Director and Vice-Chair of the Oxfordshire and BuckinghamshireNHS Mental Health Trust Board.
Goodwin has served on numerous advisory boards including the Evaluation committee for neuroscience, neurology, and psychiatry of the Agence Nationale de Recherche, France, the Wellcome Trust Neurosciences Panel, the Council of the British Association for Psychopharmacology, and Medical Research Council's Clinical fellowships panel and Advisory Board. He was elected president of the British Association for Psychopharmacology in 2004–05.
Publications
Goodwin has published extensively, authoring a book on bipolar disorder as well as numerous articles. He also regularly reviews books in the field.